DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
MWN-AI** Summary
Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Canadian innovator in AI-driven early detection of eye health issues, has made significant progress in its regulatory strategy for CARA, its AI platform. As part of a comprehensive acceleration plan initiated on October 8, 2025, Diagnos is targeting key global markets—Saudi Arabia, Canada, and the United States—for its regulatory approvals.
In Saudi Arabia, Diagnos has submitted its CARA platform for marketing approval to the Saudi Food and Drug Authority (SFDA). This submission marks a critical step in penetrating the MENA region's healthcare domain. Meanwhile, in Canada, the company is actively collaborating with Health Canada to align with relevant medical device regulations and anticipates filing its formal application within the current quarter, indicating a commitment to achieving compliance with national standards.
In the United States, following strategic discussions with the FDA, Diagnos has defined the necessary criteria for obtaining 510(k) clearance, a pivotal requirement for commercializing CARA in the lucrative U.S. market. This clarity is expected to streamline the approval process and enhance the prospects for market entry.
André Larente, CEO of Diagnos, emphasized the importance of navigating the complex regulatory landscape with precision. He underscored that securing these approvals is a priority for the company—it is seen as a critical driver of commercial growth and a boost to shareholder value.
Diagnos's AI technology aims to enhance diagnostic accuracy and improve patient outcomes globally, reflecting its commitment to advancing healthcare through innovative solutions. For further details on Diagnos and its initiatives, visit www.diagnos.com and www.sedarplus.com.
MWN-AI** Analysis
DIAGNOS Inc. is making significant strides in its regulatory strategy for its AI platform, CARA, which is poised to enhance early detection of eye-related health issues. As a financial analyst, it is imperative to closely monitor the implications of these developments for investors and stakeholders.
The company's efforts to gain marketing approval from the Saudi Food and Drug Authority (SFDA), and to align with Health Canada's medical device regulations, highlight a calculated approach to expanding its market presence in key jurisdictions. The anticipated submission for Health Canada’s formal application within the current quarter could serve as a catalyst for investor interest, particularly if the approval is granted swiftly. This milestone would establish DIAGNOS as a leading player in the Canadian AI medical tech space, potentially boosting its market capitalization and share price.
Moreover, the proactive engagement with the U.S. Food & Drug Administration (FDA) indicates that DIAGNOS is preparing for the rigorous 510(k) clearance process that could unlock substantial revenue opportunities in the lucrative U.S. market. Such strategic planning raises confidence in their ability to navigate regulatory complexities effectively, enhancing shareholder trust.
The global market for AI in healthcare is expanding, with increasing demand for innovative solutions that improve diagnostic accuracy and patient outcomes. By securing regulatory approvals in Canada, Saudi Arabia, and the U.S., DIAGNOS positions itself to capture a significant share of this growing market.
In conclusion, current developments suggest that DIAGNOS could be on the cusp of transformative growth following these regulatory milestones. Investors should remain vigilant regarding upcoming announcements and the overall market reception, as successful navigation of the regulatory landscape could lead to increased market valuation and improved shareholder returns. As always, due diligence and market diversification are recommended strategies for risk mitigation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BROSSARD, Quebec, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in applying techniques in Artificial Intelligence (AI) for the early detection of eye-related health issues, is pleased to provide an update on the regulatory pathway for its AI platform, CARA. This follows the acceleration plan announced on October 8, 2025.
The Corporation continues to execute its strategy to secure approvals in three targeted jurisdictions:
- Saudi Arabia (SFDA): DIAGNOS has formally submitted CARA for marketing approval to the Saudi Food and Drug Authority (SFDA).
- Canada (Health Canada): The Corporation is actively engaged with Health Canada to ensure full alignment with applicable medical device regulations. DIAGNOS confirms it is on track to submit its formal application for CARA in the course of this current quarter.
- United States (FDA): Following strategic meetings with the U.S. Food & Drug Administration (FDA), DIAGNOS has clarified the specific requirements to secure 510(k) clearance, paving the way for commercialization in the US market.
A Word from the CEO "Navigating the regulatory landscape for medical AI requires precision and expertise. Our team is fully focused on meeting the rigorous standards of Canada, the U.S., and Saudi Arabia," stated André Larente, CEO of DIAGNOS. "Securing these authorizations is a priority milestone that we believe will serve as a significant catalyst for commercial growth and shareholder value."
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
Additional information is available at www.diagnos.com and www.sedarplus.com.
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450-678-8882 ext. 224alarente@diagnos.ca
FAQ**
How does Diagnos Inc. ADK:CC plan to differentiate its AI platform CARA from existing eye health diagnostic tools in the markets of Saudi Arabia, Canada, and the U.S.?
Given the rigorous regulatory standards for medical devices, what challenges does Diagnos Inc. ADK:CC anticipate during the approval processes with Health Canada and the FDA?
What specific milestones does Diagnos Inc. ADK:CC aim to achieve in the next 12 months to enhance shareholder value after securing regulatory approvals for CARA?
How does Diagnos Inc. ADK:CC envision the implementation of CARA impacting patient outcomes and healthcare workflows in the regions where it seeks regulatory approval?
**MWN-AI FAQ is based on asking OpenAI questions about Diagnos Inc. (OTC: DGNOF).
NASDAQ: DGNOF
DGNOF Trading
0.71% G/L:
$0.226 Last:
20,000 Volume:
$0.22 Open:
